Company Overview

A New Approach to Cardiovascular Disease

Cardiovax LLC., is a privately held biotechnology company developing anti-inflammatory immune therapies for the leading cause of death worldwide: Cardiovascular Disease. Cardiovax therapies build protection against the accumulation of plaque within the walls of blood vessels – a process which is responsible for most heart attacks and strokes. Cardiovax has several product candidates in the pipeline that have potential to change how cardiovascluar disease is treated in the future.


The company has evolved from innovative discoveries at the Lund University Hospital, Malmö and Cedars-Sinai Medical Center and operates as an industry-academic partnership.

Cardiovascular Disease (Heart Disease) by the numbers

  • Heart disease is the leading cause of death for both men and women worldwide*
  • About 600,000 people die of heart disease in the United States every year – that's 1 in every 4 deaths*

*Reference: Murphy SL, Xu JQ, Kochanek KD. Deaths: Final data for 2010. Natl Vital Stat Rep. 2013;61(4).

Business Opportunity

  • Coronary artery disease is the most common type of heart disease, killing nearly 380,000 people annually. Coronary heart disease alone costs the United States $108.9 billion each year.*
  • Clinical trials on the effects of statins (current best of care) have shown a 20-30% reduction in cardiovascular risk, which means that about 70% of heart attacks still occurred even when patients were taking statins. These findings underscore the complexity of treating heart disease and suggest the need for new alternative therapies.*

*Chyu, Kang-yuh; Shah, Prediman K. Emerging Therapies for Atherosclerosis Prevention and Management (2011)

CardioVax's approach to treatment

Cardiovax believes that the next step in the treatment of Cardiovascular Disease is to modulate the immune system's response to inflammation. CardioVax's treatment method builds on the discovery that plaque accumulation and narrowing of arteries are a result of an immune response to oxidized-LDL (ox-LDL) which causes inflammation. Our therapies target the body's immune response to ox-LDL, teaching the body to be more tolerant of ox-LDL. If the immune system becomes more tolerant of ox-LDL, there will be less inflammation in the arteries, which will further reduce the risk of heart attack and stroke. Targeting the immune system is a promising and important new way of treating Cardiovascular Disease. Our anti-inflammatory immunotherapies could be a vital part of the treatment and prevention of Cardiovascular Disease and have the potential to reduce the risk of a heart attack or stroke.


CV Logo Footer

10100 Santa Monica Blvd., Suite 925

Los Angeles, CA 90067 United States

Tel.: 424. 263. 6364